Clearly there is some risk that SAD-ENZ will not be as successful as hoped, and therefore costs
should be kept to a minimum for the next two years until the results of clinical trials are available.
The activity of SAD-ENZ has not yet been disclosed to the public.
5.
(a)
(b)
What actions must be taken in the next two years to ensure your employer has the
best chance of getting valid patents in Europe for SAD-ENZ itself, its preparation,
and use as a slimming aid:
assuming that your employer is willing to pay Fat-Cat one million euros, and alter-
natively
assuming that your employer is not willing to pay Fat-Cat any money?
2000/DLVe/6
